Search the Newsreel

Pharvaris (NASDAQ:PHVS) Releases Earnings Results, Misses Expectations By $0.05 EPS

BV Financial (BVFL) lifts Q2 2026 earnings as loans shrink, cash rises

Las acciones de AbbVie enfrentan volatilidad con fortaleza en resultados, pero la resistencia sigue siendo clave: análisis semanal

(PHVS) as a Liquidity Pulse for Institutional Tactics

This article provides a detailed AI-driven analysis of Pharvaris N.v. (NASDAQ: PHVS), highlighting a strong near-term sentiment moving towards a long-term positive bias. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and specific entry, target, and stop-loss …

AbbVie Inc. $ABBV Shares Bought by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC increased its stake in AbbVie Inc. (NYSE:ABBV) by 7.5% in the second quarter, bringing its total holdings to 134,579 shares valued at $33.9 million. This comes as AbbVie reported strong quarterly results, beating EPS and revenue estimates, …

Earnings Flash (PHVS) Pharvaris Posts Q2 Loss 0.70 Euro a Share

Pharvaris (PHVS) boosts cash to €318M as deucrictibant nears key data and FDA date

Mobvista Schedules Board Meeting to Review 2026 Interim Results and Dividend

Pharvaris Reports Q2 2026 Results and Updates on Deucrictibant Development, Regulatory Progress and Financial Position

Pharvaris reported its Q2 2026 financial results, with cash and cash equivalents of €318 million, providing a financial runway into 2028. The company is advancing deucrictibant for bradykinin-mediated angioedema, with topline data from the pivotal Phase 3 CHAPTER-3 study expected in Q3 2026, and …

BTIG downgrades Apogee Therapeutics stock rating after AbbVie deal

BTIG has downgraded Apogee Therapeutics Inc (NASDAQ:APGE) to Neutral from Buy after shareholders approved the company's acquisition by AbbVie Inc (NYSE:ABBV) for $10.9 billion, or $135.11 per share. This deal, which sees Apogee's stock trading near its 52-week high with a significant return, is …

Should I Buy BBVA (Banco Bilbao Vizcaya Argentaria, S.A.) | AI Analysis, Technical & News Insights

Pharvaris N.V. $PHVS Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company significantly reduced its stake in Pharvaris N.V. by 44.7% in Q1 2026, selling 35,695 shares. Despite this, analysts maintain a "Moderate Buy" rating with an average price target of $50.08, while company insiders have recently sold a substantial number …

Cardinal Capital Management Inc. Buys 21,206 Shares of AbbVie Inc. $ABBV

Cardinal Capital Management Inc. increased its stake in AbbVie Inc. by 8.4% during the second quarter, purchasing an additional 21,206 shares to bring its total holdings to 273,719 shares valued at approximately $68.9 million. Institutional investors collectively own 70.23% of ABBV, and analysts maintain …

BrightView (BV) Q3 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026, at 8:30 a.m. ET CALL PARTICIPANTS Vice President of Finance and Investor Relations - Chris StoczkoPresident and Chief Executive Officer - Dale AsplundChief Financial Officer - Brett Urban TAKEAWAYS Total Revenue -- $717.6 million, …

GODSEY & GIBB, INC's AbbVie Inc(ABBV) Holding History

GODSEY & GIBB, INC holds 74,257.00 shares of AbbVie Inc (ABBV) as of June 30, 2026, valued at $18.69 million, representing 1.53% of their stock portfolio. The firm's initial trade was in Q2 2021, and they have made 9 purchases and 9 sales of …

Banco BBVA Argentina SA (BBAR) Shares Fall 4.7% -- What GF Score of 63 Tells Investors

AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision …

AbbVie (ABBV) Gains On Botox Filing, Is The 9% Discount Still There?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AbbVie (ABBV) is back in focus after Allergan Aesthetics reported that the FDA accepted a supplemental Biologics License Application for Botox Cosmetic targeting masseter muscle prominence in …

AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?

This article compares AbbVie and CVS Health as investment opportunities in 2026, highlighting their distinct business models and risk profiles. AbbVie, a biopharmaceutical giant, is favored for its focused operations and exciting growth trajectory, particularly with its immunology portfolio. CVS Health, an integrated healthcare …

AtaiBeckley (NASDAQ: ATAI) to be acquired by Eli Lilly in $6.75 cash deal plus CVR

How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?

AbbVie ABBV announced encouraging second-quarter 2026 results last month, which beat expectations for both earnings and sales. A significant portion of this growth came from the continued strength of its two blockbuster immunology medications, Skyrizi and Rinvoq, which together accounted for more than 47% …

ATAI Beckley earnings on deck as investors eye Lilly deal By Investing.com

BrightView Holdings, Inc. (7BV.F) Stock Price, News, Quote & History

This page provides an overview of BrightView Holdings, Inc. (7BV.F) stock, including its current price, news, and historical data. It details the company's performance, showing a 1.04% gain as of the reported time, and compares its trailing total returns against the S&P 500 benchmark …

Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices

Updated program delivers simplified savings, greater benefits transparency, and expanded opportunities for practice growth Introduces new rewards opportunities for customer segments, including first-time APP members, growing practices, and long-standing loyal customers IRVINE, Calif., Aug. 11, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, today …

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

AbbVie (NYSE: ABBV) is aiming high with its $10.6 billion planned purchase of Apogee Therapeutics (NASDAQ: APGE). The deal, pending regulatory approvals, is expected to close in the third quarter. The move is designed to supplement the pharmaceutical giant's already strong immunology portfolio. However, …

AbbVie Inc. $ABBV Position Cut by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its stake in AbbVie Inc. by 1.4% during the second quarter, selling 19,132 shares and now owning 1,362,464 shares worth $342.85 million. Despite this, AbbVie remains a "Moderate Buy" among analysts, with recent positive news including the acquisition of Apogee …

DBV technologies S.A. (ADR) (DBV1.SG) balance sheet

This article provides the balance sheet for DBV technologies S.A. (ADR) (DBV1.SG) as of December 31 for the years 2022 through 2025. It details key financial figures such as total assets, liabilities, equity, and share information, sourced from Yahoo Finance. The data is presented …

Carolina Wealth Advisors LLC Purchases 7,626 Shares of AbbVie Inc. $ABBV

Carolina Wealth Advisors LLC increased its stake in AbbVie Inc. by 68.6% in the second quarter, purchasing an additional 7,626 shares and bringing its total holdings to 18,741 shares valued at $4.716 million. Other institutional investors have also adjusted their positions in AbbVie, with …

Dbv Technologies SA (DBVT) Earnings Forecast: Future EPS & Revenue Growth Estimates

BBVA Banco Frances (NYSE:BBAR) Shares Pass Above 200-Day Moving Average - Should You Sell?

BBVA Banco Frances (NYSE:BBAR) shares have moved above their 200-day moving average, reaching $17.41 before settling at $17.25. The stock holds a "Moderate Buy" consensus rating with an $18.50 price target from analysts, despite a high payout ratio of 110.98% for its dividend. Institutional …

RXO, BrightView, SiteOne, ServiceNow, and Rocket Lab Shares Are Soaring, What You Need To Know

RXO, BrightView, SiteOne, ServiceNow, and Rocket Lab Shares Are Soaring, What You Need To Know What Happened? A number of stocks jumped in the afternoon session after the July jobs report showed an unexpected loss of 23,000 jobs, signaling a cooling labor market. Economists …

Pharma giants, including AbbVie, sue to block Illinois drug discount law

Major pharmaceutical companies, including AbbVie, Bristol Myers, and Novartis, have filed a lawsuit to block a new drug discount law in Illinois. The lawsuit challenges the state's 340B law, which aims to provide discounted prescription drugs. This legal action by the pharma giants indicates …

Price to book forward of BV Financial, Inc. – NASDAQ:BVFL

This article presents financial information for BV Financial, Inc. (NASDAQ: BVFL), specifically focusing on its price-to-book forward metric. It appears to be a stub or data placeholder from TradingView, indicating that the detailed financial values for this metric are yet to be populated or …

DBV Technologies (NASDAQ:DBVT) Stock Price Up 8.4% - Time to Buy?

AbbVie’s (ABBV) Botox Just Got A Step Closer To A Fifth Use

AbbVie's Botox Cosmetic has moved closer to FDA approval for a fifth aesthetic use: treating masseter muscle prominence. This potential approval is based on positive Phase 3 study results and aligns with AbbVie's strategy of expanding existing drug indications. While the company shows strong …

AbbVie, Novartis Sue Illinois Over Hospital Drug Pharmacy Law

AbbVie and Novartis AG have filed separate lawsuits against the state of Illinois, challenging a new law that regulates drugmakers' contractual agreements with pharmacies under a federal drug discount program. AbbVie claims the law violates its constitutional property rights by mandating the transfer of …